Aminocyclopentyl ethers and their preparation and pharmaceutical formulation
US5039673A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 22, 1989 |
| Grant date | Aug 13, 1991 |
| Priority date | — |
| Expiry date | Aug 22, 2009 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D295/096
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds are described of the formula (1) ##STR1## where: R.sup.1 is a hydrogen atom or a methyl group; PA1 X is cis or trans --CH.dbd.CH-- or --CH.sub.2 CH.sub.2 --, m is 2, 3 or 4 and n is 1; or X is trans --CH.dbd.CH--, m is zero and n is 3; PA1 Y is a saturated heterocyclic amino group; PA1 Alk is a C.sub.1-5 alkyl chain; PA1 l is zero or 1; PA1 p is zero, 1, 2, 3 or 4; PA1 R.sup.2 is a hydroxyl group or a group selected from --OCOR.sup.3, --CO.sub.2 R.sup.3, CONR.sup.3 R.sup.4, --SO.sub.2 NR.sup.3 R.sup.4, --NHCOR.sup.3, --NHSO.sub.2 R.sup.5, --SO.sub.2 R.sup.5, --SR.sup.5, --NR.sup.3 R.sup.4, --COR.sup.5, --NHCONR.sup.3 R.sup.4 and --NHCSNH.sub.2 ; and their physiologically acceptable salts, solvates and cyclodextrin complexes. These compounds inhibit blood platelet aggregation, bronchoconstriction and vasoconstriction and may be formulated for use as antithrombotic agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.